pebmrolizmab臨床實驗資訊

臨床實驗的資訊：
 
 實驗名：A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

概要：This is a study of pembrolizumab for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve; pembrolizumab will also be evaluated as combination therapy with cisplatin and 5-Fluorouracil (5-FU) in treatment-naïve participants. The primary study hypothesis is that pembrolizumab will provide a clinically meaningful overall response rate.

簡單介紹：針對胃癌，以及復發患者進行pembrolizumab的臨床實驗。如果已經接受治療的話，就單純使用pebmrolizumab，沒有的話，可能使用5FU、順鉑等等配合pebmrolizumab去進行。相關更詳盡的資訊請參考

https://clinicaltrials.gov/ct2/show/NCT02335411?

#胃癌